Xiaojing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiaojing Li has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Haixia Zhu
GuangZhou Women and Children's Medical Center, GuangZhou Medical University
16 shared publicationsYang Tian
GuangZhou Women and Children's Medical Center, GuangZhou Medical University
13 shared publicationsChi Hou
Department of Neurology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China
12 shared publications- Wen-Xiong Chen
Department of Neurology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China
12 shared publications Wenlin Wu
Department of Neurology Guangzhou Women and Children's Medical Center Guangzhou Medical University Guangzhou Guangdong China
12 shared publicationsBingwei Peng
GuangZhou Women and Children's Medical Center, GuangZhou Medical University
10 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 54 (8)
Pediatric hemorrhagic stroke in southern China: Analysis of 159 cases
Objective: To investigate the clinical profiles and outcomes of pediatric patients with hemorrhagic stroke in southern China. Methods: This retrospective cohort study reviewed the medical records of children hospitalized with hemorrhagic stroke at a tertiary center in southern China. The disability rate was calculated as the proportion of patients with a modified Rankin scale score of 3–5. Results: A total of 159 children (111 male and 48 female) were included. Prolonged coagulation time and cerebrovascular malformations were the most common etiologies. Disturbance of consciousness was the most frequent presenting symptom, whereas seizures predominated in children younger than 3 years and headache in older children. Computed tomography scans frequently showed temporal, parietal, or frontal lobe hemorrhages, and 60.4% of patients had multisite involvement, which was more prevalent in males. Management included conservative treatment (56.9%), surgery (33.8%), and embolization (9.4%). The mortality rate was 7.6%. Among the 108 survivors with follow-up, 78.7% achieved favorable outcomes (modified Rankin scale ≤2), whereas 21.3% developed disability, most commonly movement disorders. Conclusions: Pediatric hemorrhagic stroke in southern China exhibits distinct clinical profiles and varied etiologies. Despite the high rate of favorable outcomes, a substantial proportion of children experience disability, highlighting the need for optimized management strategies.
- 4 August 2026
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 54 (8)
Open AccessPediatric hemorrhagic stroke in southern China: Analysis of 159 cases
Objective: To investigate the clinical profiles and outcomes of pediatric patients with hemorrhagic stroke in southern China. Methods: This retrospective cohort study reviewed the medical records of children hospitalized with hemorrhagic stroke at a tertiary center in southern China. The disability rate was calculated as the proportion of patients with a modified Rankin scale score of 3–5. Results: A total of 159 children (111 male and 48 female) were included. Prolonged coagulation time and cerebrovascular malformations were the most common etiologies. Disturbance of consciousness was the most frequent presenting symptom, whereas seizures predominated in children younger than 3 years and headache in older children. Computed tomography scans frequently showed temporal, parietal, or frontal lobe hemorrhages, and 60.4% of patients had multisite involvement, which was more prevalent in males. Management included conservative treatment (56.9%), surgery (33.8%), and embolization (9.4%). The mortality rate was 7.6%. Among the 108 survivors with follow-up, 78.7% achieved favorable outcomes (modified Rankin scale ≤2), whereas 21.3% developed disability, most commonly movement disorders. Conclusions: Pediatric hemorrhagic stroke in southern China exhibits distinct clinical profiles and varied etiologies. Despite the high rate of favorable outcomes, a substantial proportion of children experience disability, highlighting the need for optimized management strategies.
- Open Access
- 8 April 2026
- Published by SAGE Publications in Journal of Central Nervous System Disease
- Vol. 18
Ofatumumab Treatment Used in Pediatric MOGAD: A Retrospective Case Series
Background: Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is a rare central nervous system demyelinating disease with a variable course, including both monophasic and relapsing phenotypes. Effective treatment options, particularly for relapsing disease, remain limited. Ofatumumab (OFA), a subcutaneous anti-CD20 monoclonal antibody approved for multiple sclerosis, has not been studied in pediatric MOGAD. This study aims to assess its safety and efficacy in this population. Objective: To describe the safety and efficacy of off-label OFA use in pediatric MOGAD patients. Patients and Methods: We conducted a retrospective case series of consecutive pediatric patients with relapsing MOGAD who received OFA. Clinical data, including relapse history, annualized relapse rate (ARR), laboratory findings, and adverse events, were collected and analyzed. Results: Three pediatric (1 female, 2 males) were included. Age at onset was 2.3, 6.1, and 2.5 years; disease duration before OFA was 6.3, 2.2, and 9.1 years; and age at OFA initiation was 8.6, 8.3, and 11.6 years. Two patients started OFA due to breakthrough relapses on mycophenolate mofetil (MMF); one switched from maintenance intravenous immunoglobulin (IVIG) for administrative convenience. Treatment durations were 12, 9, and 9 months. All patients achieved rapid B-cell depletion (CD19+ < 10 cells/μL), which was sustained in two. Serum MOG-IgG titers increased in two patients and became negative in one. Two patients remained relapse-free during OFA treatment; one experienced a single relapse at 3 months. ARR decreased in all three patients post-OFA initiation. OFA was well tolerated. Only one patient developed transient fever after the first injection, which resolved with symptomatic treatment and did not recur. Conclusion: In this small case series, OFA was generally well-tolerated and associated with a reduction in ARR, suggesting a potential role in combination therapy for relapsing pediatric MOGAD. Given the use of combination treatments in some cases, including OFA+MMF and IVIG, the role of OFA alone remains unclear. Its subcutaneous route provides practical advantages in terms of convenience. Owing to the small sample size and relapse observed in one patient, these findings remain preliminary and warrant validation in larger, prospective studies.
- 8 April 2026
- Published by SAGE Publications in Journal of Central Nervous System Disease
- Vol. 18
Open AccessOfatumumab Treatment Used in Pediatric MOGAD: A Retrospective Case Series
Background: Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is a rare central nervous system demyelinating disease with a variable course, including both monophasic and relapsing phenotypes. Effective treatment options, particularly for relapsing disease, remain limited. Ofatumumab (OFA), a subcutaneous anti-CD20 monoclonal antibody approved for multiple sclerosis, has not been studied in pediatric MOGAD. This study aims to assess its safety and efficacy in this population. Objective: To describe the safety and efficacy of off-label OFA use in pediatric MOGAD patients. Patients and Methods: We conducted a retrospective case series of consecutive pediatric patients with relapsing MOGAD who received OFA. Clinical data, including relapse history, annualized relapse rate (ARR), laboratory findings, and adverse events, were collected and analyzed. Results: Three pediatric (1 female, 2 males) were included. Age at onset was 2.3, 6.1, and 2.5 years; disease duration before OFA was 6.3, 2.2, and 9.1 years; and age at OFA initiation was 8.6, 8.3, and 11.6 years. Two patients started OFA due to breakthrough relapses on mycophenolate mofetil (MMF); one switched from maintenance intravenous immunoglobulin (IVIG) for administrative convenience. Treatment durations were 12, 9, and 9 months. All patients achieved rapid B-cell depletion (CD19+ < 10 cells/μL), which was sustained in two. Serum MOG-IgG titers increased in two patients and became negative in one. Two patients remained relapse-free during OFA treatment; one experienced a single relapse at 3 months. ARR decreased in all three patients post-OFA initiation. OFA was well tolerated. Only one patient developed transient fever after the first injection, which resolved with symptomatic treatment and did not recur. Conclusion: In this small case series, OFA was generally well-tolerated and associated with a reduction in ARR, suggesting a potential role in combination therapy for relapsing pediatric MOGAD. Given the use of combination treatments in some cases, including OFA+MMF and IVIG, the role of OFA alone remains unclear. Its subcutaneous route provides practical advantages in terms of convenience. Owing to the small sample size and relapse observed in one patient, these findings remain preliminary and warrant validation in larger, prospective studies.
- Open Access
- 23 February 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Two mild phenotype molybdenum cofactor deficiency patients with novel MOCS2 mutation and immunological treatment after COVID-19 infection
Background: Molybdenum cofactor deficiency type B (MoCD-B) is a rare autosomal recessive metabolic disorder caused by mutations in MOCS2 . Patients with mild phenotypes may experience infection-related neurological deterioration followed by partial spontaneous recovery. This study presents the first reported cases of acute encephalopathy triggered by SARS-CoV-2 infection in patients with mild MoCD-B and provides clinical insights into the course of neurological symptoms and corresponding interventions. Methods: Clinical and genetic information were collected from two patients showing acute encephalopathy, each harboring mutated molybdenum cofactor synthesis gene 2 ( MOCS2 ). Results: Both patients developed acute encephalopathy following SARS-CoV-2 infection. Clinical manifestations included motor regression, dystonia, and brain MRI abnormalities predominantly involving the bilateral globus pallidus and cerebral peduncles. Biochemical testing revealed persistently low serum uric acid and hypohomocysteinemia. Immunological analysis showed positive thyroid autoantibodies. Cerebrospinal fluid (CSF) analysis indicated elevated levels of interleukin-8 and other pro-inflammatory cytokines during the acute phase. Whole-exome sequencing identified a known pathogenic variant (c.16 C > T, p.Gln6Ter) and a novel missense variant (c.257G > T, p.Ser86Ile) in MOCS2 . Both patients received immunotherapy with intravenous immunoglobulin (IVIG) and methylprednisolone, resulting in gradual symptom improvement. Conclusion: This study expands the genetic spectrum of MoCD-B by identifying for the first time a novel MOCS2 variant (c.257G > T, p.Ser86Ile). In infants, acute neurological deterioration after infection accompanied by persistent hypouricemia and bilateral globus pallidus lesions should prompt consideration of mild MoCD-B. Our observations do not provide sufficient evidence to support routine immunotherapy for MoCD-B patients after SARS-CoV-2 infection; treatment management should be guided by established recommendations for COVID-19–associated neurological complications. Clinical trial number: Not applicable.
- 23 February 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessTwo mild phenotype molybdenum cofactor deficiency patients with novel MOCS2 mutation and immunological treatment after COVID-19 infection
Background: Molybdenum cofactor deficiency type B (MoCD-B) is a rare autosomal recessive metabolic disorder caused by mutations in MOCS2 . Patients with mild phenotypes may experience infection-related neurological deterioration followed by partial spontaneous recovery. This study presents the first reported cases of acute encephalopathy triggered by SARS-CoV-2 infection in patients with mild MoCD-B and provides clinical insights into the course of neurological symptoms and corresponding interventions. Methods: Clinical and genetic information were collected from two patients showing acute encephalopathy, each harboring mutated molybdenum cofactor synthesis gene 2 ( MOCS2 ). Results: Both patients developed acute encephalopathy following SARS-CoV-2 infection. Clinical manifestations included motor regression, dystonia, and brain MRI abnormalities predominantly involving the bilateral globus pallidus and cerebral peduncles. Biochemical testing revealed persistently low serum uric acid and hypohomocysteinemia. Immunological analysis showed positive thyroid autoantibodies. Cerebrospinal fluid (CSF) analysis indicated elevated levels of interleukin-8 and other pro-inflammatory cytokines during the acute phase. Whole-exome sequencing identified a known pathogenic variant (c.16 C > T, p.Gln6Ter) and a novel missense variant (c.257G > T, p.Ser86Ile) in MOCS2 . Both patients received immunotherapy with intravenous immunoglobulin (IVIG) and methylprednisolone, resulting in gradual symptom improvement. Conclusion: This study expands the genetic spectrum of MoCD-B by identifying for the first time a novel MOCS2 variant (c.257G > T, p.Ser86Ile). In infants, acute neurological deterioration after infection accompanied by persistent hypouricemia and bilateral globus pallidus lesions should prompt consideration of mild MoCD-B. Our observations do not provide sufficient evidence to support routine immunotherapy for MoCD-B patients after SARS-CoV-2 infection; treatment management should be guided by established recommendations for COVID-19–associated neurological complications. Clinical trial number: Not applicable.
- Open Access
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1741057
Case report: Efgartigimod treatment in two pediatric patients with chronic inflammatory demyelinating polyneuropathy
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated polyneuropathy. Early and effective immunomodulatory treatment is essential to prevent long-term disability. Efgartigimod, a human IgG1 Fc fragment, has recently been approved for adult CIDP, but its safety and efficacy in pediatric CIDP remain unstudied. We retrospectively analyzed two pediatric patients with CIDP who received efgartigimod treatment. Case report: Age at onset was 1.5 and 3.4 years; disease duration before efgartigimod was 1.5 and 3.2 years; and age at initiation was 3.0 and 6.6 years. Prior treatments included corticosteroids, maintenance intravenous immunoglobulin, mycophenolate mofetil, and rituximab in one patient, and corticosteroids plus maintenance intravenous immunoglobulin in the other. Both initiated efgartigimod due to uncontrolled relapses. At final follow-up (8 months), both showed improvement in Medical Research Council (MRC) sum scores and Inflammatory Neuropathy Cause and Treatment (INCAT) scores. One patient experienced a single relapse; the other remained relapse-free. Two mild, self-limited adverse events occurred: upper respiratory tract infection in one and transient alanine aminotransferase elevation in the other. Discussion: This is the first report of efgartigimod use in pediatric patients with CIDP. Efgartigimod was generally well tolerated, and some clinical improvements were observed in this population. However, given the small sample size, these findings should be considered preliminary and require confirmation in larger, prospective studies.
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1741057
Open AccessCase report: Efgartigimod treatment in two pediatric patients with chronic inflammatory demyelinating polyneuropathy
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated polyneuropathy. Early and effective immunomodulatory treatment is essential to prevent long-term disability. Efgartigimod, a human IgG1 Fc fragment, has recently been approved for adult CIDP, but its safety and efficacy in pediatric CIDP remain unstudied. We retrospectively analyzed two pediatric patients with CIDP who received efgartigimod treatment. Case report: Age at onset was 1.5 and 3.4 years; disease duration before efgartigimod was 1.5 and 3.2 years; and age at initiation was 3.0 and 6.6 years. Prior treatments included corticosteroids, maintenance intravenous immunoglobulin, mycophenolate mofetil, and rituximab in one patient, and corticosteroids plus maintenance intravenous immunoglobulin in the other. Both initiated efgartigimod due to uncontrolled relapses. At final follow-up (8 months), both showed improvement in Medical Research Council (MRC) sum scores and Inflammatory Neuropathy Cause and Treatment (INCAT) scores. One patient experienced a single relapse; the other remained relapse-free. Two mild, self-limited adverse events occurred: upper respiratory tract infection in one and transient alanine aminotransferase elevation in the other. Discussion: This is the first report of efgartigimod use in pediatric patients with CIDP. Efgartigimod was generally well tolerated, and some clinical improvements were observed in this population. However, given the small sample size, these findings should be considered preliminary and require confirmation in larger, prospective studies.
- Open Access
- 9 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 130
Seizure characteristics and neurological outcomes in pediatric anti-NMDAR encephalitis: a cohort study from Southern China
Objectives: This study aimed to investigate seizure characteristics, treatment and outcome of pediatric anti-NMDAR encephalitis in southern China. Methods: Clinical data of pediatric patients diagnosed with anti-NMDAR encephalitis were were retrospectively analyzed. Neurological disability and seizure severity were assessed using the mRS score and NHS3 scale, respectively. Results: Among 119 children with anti-NMDAR encephalitis, 74.8% (89/119) presented with seizures, with SE in 19.3% (23/119). The relapse rate was significantly higher in patients with seizures during the acute stage (19.1%, 17/89) compared to those without seizures (3.3%, 1/30) ( P = 0.041). The mean NHS3 score for seizures during the acute stage was 7.9 ± 0.9. Patients with > 3 seizure episodes had higher mRS pre-immunotherapy, required longer hospital stays and received more courses of intravenous methylprednisolone (IVMP) or intravenous immunoglobulin (IVIG) courses and were more likely to require Rituximab. EEG abnormalities were observed, including background slowing in all cases, epileptic discharges (37.0%), and extreme delta brush in 8.4%. 53.9% (48/89) of patients with seizure received anti-seizure medications (ASMs), 72.9% (35/48) of whom were treated with monotherapy. Seizure remission was achieved in 95.8% (46/48) within one year; 25.0% (12/48) discontinued ASMs after a median of 6.0 months (IQR 3.5, 15.0 months) without seizure recurrence, while 75.0% (36/48) continued ASMs at the last follow-up, with 5.6% (2/36) still experiencing seizures despite CSF anti-NMDAR antibodies turned negative. Patients with status epilepticus (SE) had longer diagnostic delays and higher pre-immunotherapy mRS scores, required more IVIG courses, but showed a similar prognosis compared with non-SE patients. Conclusion: Seizures are common in pediatric anti-NMDAR encephalitis; patients with more than three seizure episodes had higher mRS pre-immunotherapy and required more intensive treatment; Approximately half of the patients required ASMs, with 95.8% achieving remission within one year. The relapse rate was significantly higher in patients with seizures during the acute stage compared to those without seizures. Patients with SE had higher mRS pre-immunotherapy and required more IVIG courses, but their prognosis was similar to that of non-SE patients.
- 9 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 130
Open AccessSeizure characteristics and neurological outcomes in pediatric anti-NMDAR encephalitis: a cohort study from Southern China
Objectives: This study aimed to investigate seizure characteristics, treatment and outcome of pediatric anti-NMDAR encephalitis in southern China. Methods: Clinical data of pediatric patients diagnosed with anti-NMDAR encephalitis were were retrospectively analyzed. Neurological disability and seizure severity were assessed using the mRS score and NHS3 scale, respectively. Results: Among 119 children with anti-NMDAR encephalitis, 74.8% (89/119) presented with seizures, with SE in 19.3% (23/119). The relapse rate was significantly higher in patients with seizures during the acute stage (19.1%, 17/89) compared to those without seizures (3.3%, 1/30) ( P = 0.041). The mean NHS3 score for seizures during the acute stage was 7.9 ± 0.9. Patients with > 3 seizure episodes had higher mRS pre-immunotherapy, required longer hospital stays and received more courses of intravenous methylprednisolone (IVMP) or intravenous immunoglobulin (IVIG) courses and were more likely to require Rituximab. EEG abnormalities were observed, including background slowing in all cases, epileptic discharges (37.0%), and extreme delta brush in 8.4%. 53.9% (48/89) of patients with seizure received anti-seizure medications (ASMs), 72.9% (35/48) of whom were treated with monotherapy. Seizure remission was achieved in 95.8% (46/48) within one year; 25.0% (12/48) discontinued ASMs after a median of 6.0 months (IQR 3.5, 15.0 months) without seizure recurrence, while 75.0% (36/48) continued ASMs at the last follow-up, with 5.6% (2/36) still experiencing seizures despite CSF anti-NMDAR antibodies turned negative. Patients with status epilepticus (SE) had longer diagnostic delays and higher pre-immunotherapy mRS scores, required more IVIG courses, but showed a similar prognosis compared with non-SE patients. Conclusion: Seizures are common in pediatric anti-NMDAR encephalitis; patients with more than three seizure episodes had higher mRS pre-immunotherapy and required more intensive treatment; Approximately half of the patients required ASMs, with 95.8% achieving remission within one year. The relapse rate was significantly higher in patients with seizures during the acute stage compared to those without seizures. Patients with SE had higher mRS pre-immunotherapy and required more IVIG courses, but their prognosis was similar to that of non-SE patients.
- Open Access
- 12 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1713
Central nervous system infection by Angiostrongylus cantonensis in children: experience from Guangdong, China
Angiostrongylus cantonensis (A. cantonensis)-induced central nervous system (CNS) infection is a rare parasitic disease. Although global incidence is rising, pediatric cases remain underrecognized. This study aimed to characterize clinical features and evaluate the diagnostic utility of metagenomic next-generation sequencing (mNGS) in children. We retrospectively analyzed pediatric CNS angiostrongyliasis cases admitted to a national neurology center in Guangdong, China, between 2017 and 2024. A total of 22 pediatric patients were enrolled (median age 1.8 years; male: female = 14:8). Most cases (68.2%) began between June and October; 45.5% had confirmed or probable exposure. Fever was the most common symptom (77.2%), followed by somnolence or lethargy (63.6%) and vomiting (59.1%). No patients reported neck stiffness or hyperesthesia. All patients showed peripheral eosinophilia (median peak 24.0%, IQR 16.0%-36.0%) and cerebrospinal fluid (CSF) pleocytosis. The initial CSF eosinophil percentage exceeded 10% in 10/22 patients (45.5%), and this increased in 7/22 patients (31.8%) during follow-up. Median peak CSF eosinophil percentage was 17.2% at day 18. Among 10 patients tested for CSF cytokines, 90.0% had elevations, with IL-6 being the most common and associated with higher CSF eosinophil percentages. Serum and CSF IgG against A. cantonensis were positive in 44.4% and 46.7%, respectively. Metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid was performed in 18 of the 22 patients, and A. cantonensis was identified in all tested cases (18/18, 100%), including four who were seronegative. The median mNGS read counts of A. cantonensis were 2,453 (IQR 353.5-28,641.75), which were not significantly correlated with CSF eosinophil percentages, white blood count, or protein levels. Brain magnetic resonance imaging abnormalities (81.8%) included leptomeningeal enhancement (45.5%), ventricular enlargement (40.9%), and cortical lesions (31.8%). Electroencephalogram was abnormal in 54.5%, mainly showing slowing (50.0%) or epileptiform activity 9.1%. Albendazole was used alone in 13.6% of patients, while 86.4% received combined therapy with corticosteroids. Of the 20 patients with follow-up (median 2.5 months), all recovered clinically and radiologically without relapse or sequelae. Pediatric CNS angiostrongyliasis in Guangdong primarily affects rural children during summer-autumn. Clinical signs may be nonspecific. mNGS outperformed serology, especially in early or seronegative cases. Most patients had favorable short-term outcomes.
- 12 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1713
Open AccessCentral nervous system infection by Angiostrongylus cantonensis in children: experience from Guangdong, China
Angiostrongylus cantonensis (A. cantonensis)-induced central nervous system (CNS) infection is a rare parasitic disease. Although global incidence is rising, pediatric cases remain underrecognized. This study aimed to characterize clinical features and evaluate the diagnostic utility of metagenomic next-generation sequencing (mNGS) in children. We retrospectively analyzed pediatric CNS angiostrongyliasis cases admitted to a national neurology center in Guangdong, China, between 2017 and 2024. A total of 22 pediatric patients were enrolled (median age 1.8 years; male: female = 14:8). Most cases (68.2%) began between June and October; 45.5% had confirmed or probable exposure. Fever was the most common symptom (77.2%), followed by somnolence or lethargy (63.6%) and vomiting (59.1%). No patients reported neck stiffness or hyperesthesia. All patients showed peripheral eosinophilia (median peak 24.0%, IQR 16.0%-36.0%) and cerebrospinal fluid (CSF) pleocytosis. The initial CSF eosinophil percentage exceeded 10% in 10/22 patients (45.5%), and this increased in 7/22 patients (31.8%) during follow-up. Median peak CSF eosinophil percentage was 17.2% at day 18. Among 10 patients tested for CSF cytokines, 90.0% had elevations, with IL-6 being the most common and associated with higher CSF eosinophil percentages. Serum and CSF IgG against A. cantonensis were positive in 44.4% and 46.7%, respectively. Metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid was performed in 18 of the 22 patients, and A. cantonensis was identified in all tested cases (18/18, 100%), including four who were seronegative. The median mNGS read counts of A. cantonensis were 2,453 (IQR 353.5-28,641.75), which were not significantly correlated with CSF eosinophil percentages, white blood count, or protein levels. Brain magnetic resonance imaging abnormalities (81.8%) included leptomeningeal enhancement (45.5%), ventricular enlargement (40.9%), and cortical lesions (31.8%). Electroencephalogram was abnormal in 54.5%, mainly showing slowing (50.0%) or epileptiform activity 9.1%. Albendazole was used alone in 13.6% of patients, while 86.4% received combined therapy with corticosteroids. Of the 20 patients with follow-up (median 2.5 months), all recovered clinically and radiologically without relapse or sequelae. Pediatric CNS angiostrongyliasis in Guangdong primarily affects rural children during summer-autumn. Clinical signs may be nonspecific. mNGS outperformed serology, especially in early or seronegative cases. Most patients had favorable short-term outcomes.
- Open Access
- 27 October 2025
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (6) , 2669-2681
Short-Term Outcomes and Immunologic Mechanisms of Adrenocorticotropic Hormone in Infantile Epileptic Spasm Syndrome: A Multicenter Prospective Trial in Southern China
Introduction Adrenocorticotropic hormone (ACTH) is a first-line drug and standard therapy in infantile epileptic spasm syndrome (IESS) with different response rates. The mechanism of ACTH for treatment of IESS remains incompletely understood. This study aimed to evaluate short-term outcomes and immunologic mechanisms of ACTH in treating pediatric patients with IESS. Methods A multicenter prospective trial of pediatric patients with IESS treated with ACTH over 2 weeks was performed. Short-term responders were defined as those with resolution of epileptic spasms and hypsarrhythmia (if present) at day 14 without epileptic spasm recurrence over 30 days after ACTH therapy, while non-responders included those with persistent spasms or hypsarrhythmia after treatment, or recurrence within 30 days. The risk factors for short-term efficacy were analyzed. The receiver operating characteristic (ROC) curve analysis was adopted to reveal the optimal critical value of peripheral blood lymphocyte subpopulations before ACTH treatment. Results Among 151 included pediatric patients, 44 (29.1%) were short-term responders. The presence of hypsarrhythmia on pre-therapy electroencephalogram (EEG) was a risk factor for the short-term efficacy (p = 0.029). A total of 81 patients accepted lymphocyte subpopulation investigation. The short-term responder group had a lower percentage of CD3+CD8+ T cells (p = 0.080) and a higher CD3+CD4+/CD3+CD8+ ratio (p = 0.077) compared to the non-responder group, but the differences were not statistically significant. ROC analysis yielded area under the curve (AUC) values of 0.599 for CD3+CD8+ T cell percentage and 0.600 for the CD3+CD4+/CD3+CD8+ratio. Patients with a CD3+CD8+ T cell percentage below 19.495% (p = 0.04) and a CD3+CD4+/CD3+CD8+ above 2.585 (p = 0.013) had a significantly higher short-term responder rate to ACTH therapy. Conclusion About 30% children with IESS were short-term responders to ACTH therapy. The presence of hypsarrhythmia on the pre-therapy EEG was a risk factor for short-term efficacy of ACTH administration. The CD3+CD8+ T cell percentage and CD3+CD4+/CD3+CD8+ ratio may exhibit a predictive capacity.
- 27 October 2025
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (6) , 2669-2681
Open AccessShort-Term Outcomes and Immunologic Mechanisms of Adrenocorticotropic Hormone in Infantile Epileptic Spasm Syndrome: A Multicenter Prospective Trial in Southern China
Introduction Adrenocorticotropic hormone (ACTH) is a first-line drug and standard therapy in infantile epileptic spasm syndrome (IESS) with different response rates. The mechanism of ACTH for treatment of IESS remains incompletely understood. This study aimed to evaluate short-term outcomes and immunologic mechanisms of ACTH in treating pediatric patients with IESS. Methods A multicenter prospective trial of pediatric patients with IESS treated with ACTH over 2 weeks was performed. Short-term responders were defined as those with resolution of epileptic spasms and hypsarrhythmia (if present) at day 14 without epileptic spasm recurrence over 30 days after ACTH therapy, while non-responders included those with persistent spasms or hypsarrhythmia after treatment, or recurrence within 30 days. The risk factors for short-term efficacy were analyzed. The receiver operating characteristic (ROC) curve analysis was adopted to reveal the optimal critical value of peripheral blood lymphocyte subpopulations before ACTH treatment. Results Among 151 included pediatric patients, 44 (29.1%) were short-term responders. The presence of hypsarrhythmia on pre-therapy electroencephalogram (EEG) was a risk factor for the short-term efficacy (p = 0.029). A total of 81 patients accepted lymphocyte subpopulation investigation. The short-term responder group had a lower percentage of CD3+CD8+ T cells (p = 0.080) and a higher CD3+CD4+/CD3+CD8+ ratio (p = 0.077) compared to the non-responder group, but the differences were not statistically significant. ROC analysis yielded area under the curve (AUC) values of 0.599 for CD3+CD8+ T cell percentage and 0.600 for the CD3+CD4+/CD3+CD8+ratio. Patients with a CD3+CD8+ T cell percentage below 19.495% (p = 0.04) and a CD3+CD4+/CD3+CD8+ above 2.585 (p = 0.013) had a significantly higher short-term responder rate to ACTH therapy. Conclusion About 30% children with IESS were short-term responders to ACTH therapy. The presence of hypsarrhythmia on the pre-therapy EEG was a risk factor for short-term efficacy of ACTH administration. The CD3+CD8+ T cell percentage and CD3+CD4+/CD3+CD8+ ratio may exhibit a predictive capacity.
- 24 September 2025
- Published by Elsevier in Brain and Development
- Vol. 47 (5) , 104444
Relapse in pediatric anti-N-methyl-d-aspartate receptor encephalitis: A cohort study in one of the national children's medical center in China
- 24 September 2025
- Published by Elsevier in Brain and Development
- Vol. 47 (5) , 104444
Relapse in pediatric anti-N-methyl-d-aspartate receptor encephalitis: A cohort study in one of the national children's medical center in China
- Open Access
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Ofatumumab in pediatric multiple sclerosis: a case series
Pediatric-onset multiple sclerosis (POMS), accounting for ~5% of all MS cases, is a chronic immune-mediated demyelinating disorder of the central nervous system. Relapse prevention remains a challenge, and B cells play a central role in the pathogenesis. Ofatumumab (OFA), a fully human anti-CD20 monoclonal antibody, is approved for adult MS. To assess the safety and efficacy of off-label OFA use in pediatric MS patients. We retrospectively analyzed clinical data from four pediatric patients with MS who received OFA. Retrospective case series. Four pediatric MS patients received OFA as disease-modifying treatment at ages ranging from 9.7 to 12.8 years for durations between 6 and 20 months. Three patients received OFA treatment for uncontrolled relapses, while one switched from rituximab. After the initial treatment phase of OFA, B-cell depletion was achieved in three patients, and this depletion was not consistently maintained throughout the maintenance phase. All patients remained relapse-free, with no new or enlarging T2 lesions or contrast-enhancing lesions observed on MRI or EDSS progression. The annual relapse rate after OFA treatment decreased compared with that before OFA treatment. One patient reported mild adverse events, including transient fever and atopic dermatitis, all of which were manageable. Ofatumumab showed favorable tolerability and potential benefit in this small pediatric MS cohort. Its subcutaneous administration offers practical advantages. While these findings suggest feasibility, the limited evidence precludes clinical recommendation at this stage. Larger prospective studies are warranted.
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Open AccessOfatumumab in pediatric multiple sclerosis: a case series
Pediatric-onset multiple sclerosis (POMS), accounting for ~5% of all MS cases, is a chronic immune-mediated demyelinating disorder of the central nervous system. Relapse prevention remains a challenge, and B cells play a central role in the pathogenesis. Ofatumumab (OFA), a fully human anti-CD20 monoclonal antibody, is approved for adult MS. To assess the safety and efficacy of off-label OFA use in pediatric MS patients. We retrospectively analyzed clinical data from four pediatric patients with MS who received OFA. Retrospective case series. Four pediatric MS patients received OFA as disease-modifying treatment at ages ranging from 9.7 to 12.8 years for durations between 6 and 20 months. Three patients received OFA treatment for uncontrolled relapses, while one switched from rituximab. After the initial treatment phase of OFA, B-cell depletion was achieved in three patients, and this depletion was not consistently maintained throughout the maintenance phase. All patients remained relapse-free, with no new or enlarging T2 lesions or contrast-enhancing lesions observed on MRI or EDSS progression. The annual relapse rate after OFA treatment decreased compared with that before OFA treatment. One patient reported mild adverse events, including transient fever and atopic dermatitis, all of which were manageable. Ofatumumab showed favorable tolerability and potential benefit in this small pediatric MS cohort. Its subcutaneous administration offers practical advantages. While these findings suggest feasibility, the limited evidence precludes clinical recommendation at this stage. Larger prospective studies are warranted.
- Open Access
The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series